ProtoKinetix, Inc.
ProtoKinetix, Inc. (PKTX): 1 pipeline candidate · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.5 months
0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for ProtoKinetix, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0M
Cash
$607
Quarterly Burn
$4K
Runway
0.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| aagp | Phase 1 |
Frequently asked questions
How many drug candidates are in ProtoKinetix, Inc.'s pipeline?
ProtoKinetix, Inc. (PKTX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is ProtoKinetix, Inc.'s lead drug candidate?
ProtoKinetix, Inc.'s most advanced tracked candidate is aagp (Phase 1) for Dry eye.
What is ProtoKinetix, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ProtoKinetix, Inc. has approximately 0.5 months of cash runway.
What is ProtoKinetix, Inc.'s market capitalization?
ProtoKinetix, Inc.'s market capitalization is approximately $2.0M.
Who is the CEO of ProtoKinetix, Inc.?
Mr. Michael Richard Guzzetta CPA is the chief executive officer of ProtoKinetix, Inc. (PKTX).
Get the full picture on ProtoKinetix, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.